Table 2.
Comparison of clinical and molecular features of BRAF mutant cancers stratified by PRDM5 methylation status (n = 214)
| PRDM5Methylated | PRDM5Unmethylated | P value | |
|---|---|---|---|
| N BRAF mutant cancers | 77/214 (36.0%) | 137/214 (64.0%) | |
| Average Age | 72.7 | 75.0 | 0.1 |
| Gender (Female) | 48/77 (62.3%) | 91/137 (66.4%) | 0.6 |
| Location (Proximal) | 62/72 (86.1%) | 102/120 (84.2%) | 1.0 |
| AJCC stage I/II | 36/65 (55.4%) | 74/105 (70.5%) | <0.05 |
| AJCC stage III/IV | 29/65 (44.6%) | 31/105 (29.5%) | |
| Mucinous | 9/34 (26.5%) | 28/62 (45.2%) | 0.08 |
| Differentiation (poor) | 15/34 (44.1%) | 23/62 (37.1%) | 0.5 |
| MSI High | 37/77 (48.1%) | 83/137 (60.6%) | 0.09 |
| CIMP High | 59/73 (80.8%) | 95/132 (72.0%) | 0.2 |
| p53 Mutation | 13/39 (33.3%) | 15/68 (22.1%) | 0.3 |
| Nuclear Beta-Catenin | 16/33 (48.5%) | 20/59 (33.9%) | 0.2 |
Significant p values indicated in bold text.